91 related articles for article (PubMed ID: 9245710)
1. Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III.
Parker JC; VanVolkenburg MA; Nardone NA; Hargrove DM; Andrews KM
Biochem Biophys Res Commun; 1997 Jul; 236(3):665-9. PubMed ID: 9245710
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity.
Yang G; Li L
J Chin Med Assoc; 2003 Apr; 66(4):210-6. PubMed ID: 12854872
[TBL] [Abstract][Full Text] [Related]
3. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone.
Silver PJ; Lepore RE; O'Connor B; Lemp BM; Hamel LT; Bentley RG; Harris AL
J Pharmacol Exp Ther; 1988 Oct; 247(1):34-42. PubMed ID: 2845058
[TBL] [Abstract][Full Text] [Related]
5. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
[TBL] [Abstract][Full Text] [Related]
6. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
7. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion.
Cheung P; Yang G; Boden G
Metabolism; 2003 Nov; 52(11):1496-500. PubMed ID: 14624413
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
10. Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion.
Parker JC; VanVolkenburg MA; Ketchum RJ; Brayman KL; Andrews KM
Biochem Biophys Res Commun; 1995 Dec; 217(3):916-23. PubMed ID: 8554616
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects.
Chiu YJ; Hu SH; Reid IA
J Pharmacol Exp Ther; 1999 Jul; 290(1):16-9. PubMed ID: 10381754
[TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
Sato N
Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
[No Abstract] [Full Text] [Related]
13. The effect of phosphodiesterase III inhibitors on human neutrophil function.
Mikawa K; Akamatsu H; Nishina K; Shiga M; Maekawa N; Obara H; Niwa Y
Crit Care Med; 2000 Apr; 28(4):1001-5. PubMed ID: 10809273
[TBL] [Abstract][Full Text] [Related]
14. [How to use PDE III inhibitors].
Goto Y
Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
[No Abstract] [Full Text] [Related]
15. Cyclic AMP-phosphodiesterase IIIA1 inhibitors decrease cytosolic Ca2+ concentration and increase the Ca2+ content of intracellular storage sites in human platelets.
Roevens P; de Chaffoy de Courcelles D
Biochem Pharmacol; 1993 Jun; 45(11):2279-82. PubMed ID: 8390836
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 3 inhibitors suppress oocyte maturation and consequent pregnancy without affecting ovulation and cyclicity in rodents.
Wiersma A; Hirsch B; Tsafriri A; Hanssen RG; Van de Kant M; Kloosterboer HJ; Conti M; Hsueh AJ
J Clin Invest; 1998 Aug; 102(3):532-7. PubMed ID: 9691090
[TBL] [Abstract][Full Text] [Related]
17. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Gillespie E
Biochem Pharmacol; 1988 Jul; 37(14):2866-8. PubMed ID: 2456068
[No Abstract] [Full Text] [Related]
19. Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice.
Degerman E; Manganiello V; Holst JJ; Ahrén B
Eur J Pharmacol; 2004 Sep; 498(1-3):319-23. PubMed ID: 15364011
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes.
Belhassen L; Kelly RA; Smith TW; Balligand JL
J Clin Invest; 1996 Apr; 97(8):1908-15. PubMed ID: 8621775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
